HDAC4 and hepatocellular carcinoma: found that in sorafenib-resistant HCC patients, the histone deacetylase HDAC4 in complex with the transcription factor MEF2D to form a complex that directly binds to the SPRY4 promoter region to inhibit the transcriptional level of SPRY4, leading to overactivation of the MAPK/ERK pathway.